FDA Accepts Supplement for Oxcarbazepine ANDA215332
The FDA has accepted a supplemental application for oxcarbazepine under ANDA215332 from sponsor AUCTA.
Asset / Drug
Drug and asset intelligence for AUCTA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.